Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03435796 · ClinicalTrials.gov registry record · Phase 2

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

A Phase 2 study of Neoplasms, sponsored by Celgene.

Recruiting
Registry status
Phase 2
Development phase
1,541
Enrollment target
20
Study locations

NCT03435796 is a Phase 2 study of Neoplasms that is actively recruiting participants, run by Celgene. The registered enrollment target is 1,541 participants, roughly in line with the 1,612-participant average among 158 other Neoplasms trials with a reported enrollment target. The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03435796, a Phase 2 study of Neoplasms, is actively recruiting participants, sponsored by Celgene.

RECRUITING
Registry status
Phase 2
Development phase
1,541 participants
Enrollment target
20
Study locations

Study Summary

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

Conditions Studied

Neoplasms

Interventions

  • GENETIC Gene-modified (GM) T cell therapy

Study Locations (20)

California

  • City Of Hope - Duarte
  • University Of California San Diego Moores Cancer Center - La Jolla
  • Local Institution - 01206 - Los Angeles
  • Local Institution - 01043 - Sacramento
  • University of California, San Francisco- California - San Francisco
  • UCLA Medical Centre-Santa Monica - Santa Monica
  • Stanford Cancer Center - Stanford

Arizona

  • Banner MD Anderson Cancer Center - Gilbert
  • Mayo Clinic Phoenix - Phoenix
  • Arizona Cancer Center - Scottsdale
  • Local Institution - 01021 - Tucson

Florida

  • The Mayo Clinic - Jacksonville, Davis-E - Jacksonville
  • Baptist Cancer Center - Miami
  • Local Institution - 01035 - Orlando
  • H. Lee Moffitt Cancer Center and Research Institute University of South Florida - Tampa

Colorado

  • University Of Colorado Cancer Center - Aurora
  • Colorado Blood Cancer Institute - Denver

Alabama

  • University of Alabama Birmingham - Birmingham

Connecticut

  • Yale Cancer Center - New Haven

District of Columbia

  • Local Institution - 01050 - Washington D.C.

Trial Details

FieldValue
Enrollment Target 1,541 participants
Start Date 2018-07-19
Est. Completion 2036-11-30
Phase Phase 2

Sponsor

Celgene

308 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03435796

The ClinicalTrials.gov registry entry for NCT03435796 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,541 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 1,612-participant average among 158 other Neoplasms trials with a reported enrollment target. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Gene-modified (GM) T cell therapy is the first listed.

NCT03435796 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT03435796 about?

NCT03435796 is a clinical study titled "Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells". This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least o...

What is the current status of trial NCT03435796?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,541 participants. The study started on 2018-07-19. Estimated completion is 2036-11-30.

What conditions does trial NCT03435796 study?

This clinical trial studies the following conditions: Neoplasms.

What interventions are being tested in trial NCT03435796?

The interventions under investigation include: Gene-modified (GM) T cell therapy (GENETIC).

Who is sponsoring clinical trial NCT03435796?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03435796 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.